Year
2023
-
Study: Survivors of Hodgkin Lymphoma Show Signs of Dementia in Early Adulthood
-
Gilead Sciences’ Sunlenca Gains FDA Approval for HIV Type 1
-
New method predicts the right treatment for breast cancer patients
-
Study Results Show Direct Evidence of Serotonin Disruption Linked With Depression
-
Roche’s Lunsumio Gets Accelerated Approval for Later-Line Follicular Lymphoma
-
AZ announces US fast track designation for IL-5 inhibitor Fasenra
-
FDA slaps partial hold on Biogen, InnoCare MS drug
-
FDA Approves Actemra for Hospitalized Adults with COVID-19
-
FDA Approves Briumvi for Relapsing Multiple
-
ACELYRIN acquires ValenzaBio, strengthens immunology position